Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapport TherapeuticsRAPP +0.82%14 Revenue per Share is $0.42 as of Jun. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 5 warning signs investors should review. Among 768 Biotechnology companies, Rapport Therapeutics ranks worse than 130208.2% on this metric.
Rapport Therapeutics's revenue per share for the
three
months ended in Jun. 2026 was $0.00.
Rapport Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.42.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Rapport Therapeutics's Revenue per Share or its related term are showing as below:
RAPP's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 2.95 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Rapport Therapeutics Revenue per Share Related Terms
Rapport Therapeutics Revenue per Share Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPP vs AUPH, PVLA, GLUE: Revenue per Share Comparison
For the Biotechnology subindustry, Rapport Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's PS Ratio falls into.
Rapport Therapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Rapport Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Revenue per Share of $0.42 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Rapport Therapeutics and its competitors. According to the industry distribution chart, Rapport Therapeutics ranks #999999 out of 768 companies in the Biotechnology industry.
Is Rapport Therapeutics' Revenue per Share too high?
Rapport Therapeutics' current Revenue per Share is $0.42. The Biotechnology industry median Revenue per Share is 2.95. Rapport Therapeutics' value of $0.42 is 85.8% below this industry median. Based on the distribution chart, Rapport Therapeutics ranks #999999 out of 768 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Revenue per Share compare to AUPH and PVLA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #999999 out of 768 companies for Revenue per Share. This places Rapport Therapeutics in the lower half of its industry. The industry median Revenue per Share is 2.95. Rapport Therapeutics' value of $0.42 is 85.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 2.95, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Revenue per Share of $0.42 is 85.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Rapport Therapeutics and its competitors. For the Biotechnology industry, the median Revenue per Share is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Revenue per Share is $0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Revenue per Share of $0.42. The current Revenue per Share is $0.42 and 85.8% below the Biotechnology industry median of 2.95. Rapport Therapeutics' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Revenue per Share is $0.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
